Artwork

Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Is HER2 targeting on the horizon for urothelial carcinoma?

16:16
 
Distribuie
 

Manage episode 397347959 series 3389426
Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

touchFOCUS for touchONCOLOGY

A genitourinary medical oncologist considers the potential for targeting HER2 in the treatment of urothelial carcinoma, including the rationale for HER2 as a target, approaches to HER2 testing, the latest data on emerging HER2-targeted therapies and the potential implications for future clinical practice.

The expert:

  • Dr Vadim Koshkin - University of California San Francisco, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Seagen Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

  continue reading

102 episoade

Artwork
iconDistribuie
 
Manage episode 397347959 series 3389426
Content provided by touchpodcast. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by touchpodcast or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

touchFOCUS for touchONCOLOGY

A genitourinary medical oncologist considers the potential for targeting HER2 in the treatment of urothelial carcinoma, including the rationale for HER2 as a target, approaches to HER2 testing, the latest data on emerging HER2-targeted therapies and the potential implications for future clinical practice.

The expert:

  • Dr Vadim Koshkin - University of California San Francisco, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Seagen Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: touchoncology.com

  continue reading

102 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință